- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer Center
NCI CANCERLIT® Search: Mouth Cancer - January 2002
National Cancer Institute®
Last Modified: January 1, 2002
Table of Contents
1
UI - 11089191
AU - Tochigi H; Nakao Y; Horiuchi Y; Toyama Y
TI -
Metastatic malignant melanoma in the hand muscle--a case report.
SO - Hand Surg 2000 Jul;5(1):69-72
AD - Department of Orthopaedic Surgery, School of Medicine, Keio University,
35 Shinanomachi, Shinjuku-ku, Tokyo 160, Japan.
2
UI - 11425214
AU - Markkanen-Leppanen M; Suominen E; Lehtonen H; Asko-Seljavaara S
TI -
Free flap reconstructions in the management of oral and pharyngeal
cancer.
SO - Acta Otolaryngol 2001 Apr;121(3):425-9
AD - Department of Otolaryngology, Helsinki University, Central Hospital,
Finland. mari.markkanen-leppanen@hus.fi
Fifty patients who had undergone microvascular free flap reconstruction
of the oral cavity or pharynx for malignancy between 1989 and 1995 were
retrospectively analysed to find factors predicting postoperative
complications and outcomes. The mean follow-up time was 2.6 years. More
than half (26/50) of the patients had a stage IV malignancy and 10
patients had a recurrent tumour. The overall flap success rate, with 2
flap losses, was 96%. Postoperative medical complications occurred in
29/50 (58%) cases. The recipient site of 10/50 (20%) flaps required
re-exploration. Mortality was 2%, with 1 death occurring within 30 days.
The mean survival rate after the microvascular operation was 1.6 years,
and the 3- and 5-year survival rates were 42% and 23%, respectively.
Patients with an oropharyngeal tumour seemed to have the best prognosis
and those with a hypopharyngeal tumour the poorest. Men had a threefold
greater risk of dying within < 1 year postoperatively compared with
women. Tumour stage was the strongest attribute influencing survival.
The risk of death after the microvascular procedure increased 2.8-fold
when the stage advanced from II to III or from II to IV. None of the
tested variables alone could predict complications.
3
UI - 11423019
AU - Ankem MK; Hartanto VH; Han KR; Ferlise VJ; Bancila E; Cummings KB;
TI -
DiPaola RS
Metastatic renal cell carcinoma presenting as an oral tumor.
SO - Can J Urol 2001 Jun;8(3):1295-6
AD - Division of Urology, Robert Wood Johnson Medical School, University of
Medicine and Dentistry of New Jersey, New Brunswick, NJ 08903-0019, USA.
Metastatic cancer presenting as an oral lesion is exceedingly uncommon.
To the best of our knowledge this is the first reported instance of
renal cell carcinoma presenting initially as an oral lesion.
4
UI - 11432667
AU - Higa M; Kinjo T; Miyagi J; Sakumoto N; Iwamasa T; Kishaba M; Sunakawa H
TI -
Differences in EBNA2 and LMP-1 carboxy terminal region sequences of
Epstein-Barr virus type A between the tumors in a multiple cancer
patient.
SO - Pathol Res Pract 2001;197(6):401-9
AD - Department of Pathology, Ryukyu University School of Medicine,
Nishihara, Okinawa, Japan.
Using PCR, type A Epstein-Barr virus (EBV) infection was demonstrated in
a squamous cell carcinoma of the maxilla (in a 52-year-old man) and the
tongue of the same patient 18 years later (at the age of 70).
Furthermore, at the age of 72, this patient developed an EBV-infected
anaplastic large cell lymphoma. Analysis of the terminal regions of the
EBV genome revealed a monoclonal proliferation of EBV-infected lymphoma
cells. However, sequence analysis of the EBV revealed a slight
difference in the EBNA2 regions between the virus-infected lymphoma and
the squamous cell carcinomas. The mutations at 48991 (G-->T) and 48998
(C-->A) were demonstrated in the lymphoma. Although the squamous cell
carcinoma of the tongue occurred after an interval of 18 years, the
mutation site in the carcinomas was the same, 49137 (A-->G), as compared
with B95-8 strain EBV EBNA2. The mutations at 48991 and at 49137 were
associated with amino acid changes, Arg-->Met and Thr-->Ala,
respectively, but the alteration at 48998 was a silent mutation.
Thirty-bp deletion in the LMP-1 carboxy terminal region was demonstrated
in the virus-infected lymphoma, but not in the squamous cell carcinomas.
On the other hand, HTLV-1 proviral DNA (tax, gag and env) was not
detected in the lymphoma, nor was HPV demonstrated in the squamous cell
carcinomas, although Okinawa is known as an HTLV-1 and HPV prevalence
region. The T-cell receptor beta gene rearrangement was demonstrated in
the lymphoma, but the t(2;5) fusion transcript was not detected using
PCR. Cytogenetic analysis of the lymphoma cells showed a complex
hypertriploid karyotype with 76XY. The type A EBV infection might play a
role in the carcinogenesis of the tumors of our patient. Interestingly,
the infected virus genome sequences, the EBNA2 and LMP-1 regions, which
were closely associated with carcinogenesis in the squamous cell
carcinomas and the lymphoma, showed slight differences.
5
UI - 11484979
AU - Grammatica L; Piepoli S; D'Auria C; Achille G; Marzullo F; Zito FA;
TI -
Labriola A; Salvatore C; Paradiso A
Primary tumours neoangiogenesis and P53 expression in oral carcinoma
patients.
SO - J Exp Clin Cancer Res 2001 Jun;20(2):225-30
AD - Otorhinolaryngology Unit, National Cancer Institute, Bari, Italy.
Paraffin embebbed tumour tissues from 47 T1-2 N0-1 M0 primary oral
squamous carcinoma have been utilized for immunohistochemical analysis
of p53 expression (moab DO-7) and microvessel density (MVD) analysis
(moab CD34). Fifty percent of cases showed p53 immunostaining with an
average of 21% of p53 positive cells. A strong trend for a longer
survival in patients with tumor p53- versus p53+ was evidenced (median
survival: 12 months versus not reached, respectively; p=0.08 by log-rank
test). A mean value of 27 MVD was found. The probability of overall
survival did not result significantly different in the subgroups of
tumours with high and low MVD (median survival: 6 months versus 6
months, respectively; p=0.24). Cox multivariate analysis confirmed that
the only prognostic factor significantly related to the overall survival
was clinical nodal status (O.R.=2.7; 95% C.I. 1.09-6.9), while p53
status only approached the statistical significance (O.R.=2.5; 95% C.I.
0.96-6.5; p=0.06).
6
UI - 11488133
AU - Sanchez Jimenez J; Dean Ferrer A; Alamillos Granados F; Ruiz Masera JJ;
TI -
Villar Pastor C; Garcia Lopez A; Penalba Manegold M
Adult rhabdomyoma in the masticatory area. New case presentation and
review of the literature.
SO - Med Oral 2001 Jan-Feb;6(1):64-8
AD - Servicio de Cirugia Oral y Maxilofacial, Hospital Universitario Reina
Sofia, Cordoba, Espana. jsanchezjimenez@uole.com
Adult rhabdomyoma is a rare neoplasm of mesenchymal origin which
represents approximately 2% of tumors with skeletal muscle
differentiation. There are only about 100 cases reported in the
literature. It is a benign tumor occurring most frequently in the head
and neck region, which affects predominantly male population of a mean
age ranging from 54 to 60. The purpose of this article is to present a
new case of adult rhabdomyoma located in the masticatory area, arising
as a slow-growing mass bulging in the left-side jugal mucosa and
temporal region. The most common location for adult rhabdomyoma is the
pharyngeal cavity. This type of tumor appears as a solitary mass, though
occasionally may be multifocal. This tumor being of low occurrence,
correct diagnosis can prevent aggressive surgery.
7
UI - 11498549
AU - Bagla P; Marshall E
TI -
Clinical research. Hopkins reviews investment in Indian cancer drug
trial.
SO - Science 2001 Aug 10;293(5532):1024
8
UI - 11167138
AU - Kerdpon D; Sriplung H
TI -
Factors related to delay in diagnosis of oral squamous cell carcinoma in
southern Thailand.
SO - Oral Oncol 2001 Feb;37(2):127-31
AD - Stomatology Department, Faculty of Dentistry, Prince of Songkla
University, Haad Yai, Songkhla 90112, Thailand.
kduangpo@ratree.psu.ac.th
The factors related to patient, professional and total delay in 161 oral
squamous cell carcinoma (OSCC) patients attending for treatment at a
university hospital in southern Thailand were investigated. About 42 and
20% of these patients had a patient delay of more than 1 month and 3
months, respectively. About half of the patients received proper
management from health care professionals (HCPs) on their first
consultation. Traditional herbal medication use was significantly
associated with prolonged patient delay (hazard ratio [HR] 0.46, 95%
C.I. 0.28-0.76). None of the variables investigated had a significant
association with professional delay. Traditional herbal medication use
also significantly prolonged total delay (HR 0.45, 95% C.I. 0.27-0.74).
Buddhists had shorter total delay than Muslims (HR 0.68, 95% C.I.
0.49-0.95). The present study indicates that both patients and HCPs are
responsible for the diagnostic delay. A health education campaign about
OSCC and the use of traditional herbal medication is recommended to
shorten patient delay. Continuing education on oral cancer and precancer
for HCPs and clarification of the referral system are needed to effect a
major reduction in professional delay.
9
UI - 11167139
AU - Fujimoto R; Kamata N; Yokoyama K; Ueda N; Satomura K; Hayashi E;
TI -
Nagayama M
Expression of telomerase components in oral keratinocytes and squamous
cell carcinomas.
SO - Oral Oncol 2001 Feb;37(2):132-40
AD - First Department of Oral and Maxillofacial Surgery, School of Dentistry,
Tokushima University, 3-18-15 Kuramoto-cho, Tokushima City, Tokushima
770-8504, Japan.
Telomerase activity was measured using a telomeric repeat amplification
protocol (TRAP), and expressions of the telomerase components,
telomerase associated protein 1 (hTEP1), human telomerase RNA component
(hTR), and human telomerase reverse transcriptase (hTERT) were measured
by reverse transcriptase-polymerase chain reaction (RT-PCR) in cultured
normal oral keratinocytes and oral squamous cell carcinoma (SCC) cells.
Telomerase localization was analyzed by in situ hybridization (ISH) in
normal, precancerous and cancerous oral tissues. There was a strong
correlation of telomerase activity with the expression levels of hTERT
but not with hTEP1 or hTR mRNA in the cultured cells. Not only hTEP1 and
hTR but also hTERT expression were detected in the basal cells of normal
oral mucosa, and the cells expressing these mRNAs were also seen in the
upper layer of leukoplakia of gingiva, and a heterogeneous pattern of
expression was observed in the oral SCC tissues. These results indicate
that there are at least two steps in the increase of telomerase activity
during carcinogenesis in oral squamous cells; a change in distribution
of cells expressing these telomerase components and the over-expression
of hTERT gene in individual cells.
10
UI - 11167141
AU - Uobe K; Masuno K; Fang YR; Li LJ; Wen YM; Ueda Y; Tanaka A
TI -
Detection of HPV in Japanese and Chinese oral carcinomas by in situ PCR.
SO - Oral Oncol 2001 Feb;37(2):146-52
AD - Department of Oral Pathology, Osaka Dental University, 8-1
Kuzuhahanazono-cho, Hirakata-shi, Osaka 573-1121, Japan.
Human papillomavirus (HPV) is established as the cause of almost 100% of
cervical carcinomas. However, the association of HPV with oral squamous
cell carcinomas (SCCs) is less well understood. We examined the
prevalence of HPV in oral SCCs in samples of Japanese and Chinese
populations. Using in situ polymerase chain reaction (PCR) analysis
(MY09 and MY11 consensus primers), HPV was detected in the nucleus of
epithelia and tumor cells in oral lesions. Analysis revealed the
specific presence of HPV DNA in all cases of SCC in our Japanese (10/10)
and Chinese (10/10) population samples. These results suggest that HPV
infection could be one of several risk factors contributing to oral SCC
in Japanese and Chinese.
11
UI - 11167142
AU - Homann N; Tillonen J; Rintamaki H; Salaspuro M; Lindqvist C; Meurman JH
TI -
Poor dental status increases acetaldehyde production from ethanol in
saliva: a possible link to increased oral cancer risk among heavy
drinkers.
SO - Oral Oncol 2001 Feb;37(2):153-8
AD - Research Unit of Alcohol Diseases, Helsinki University Central Hospital,
Helsinki, Finland.
Epidemiological data support evidence that poor dental status increases
oral cavity cancer risk especially among heavy alcohol consumers, but
the causality of this finding is unclear. The enzymatic conversion of
ethanol by the physiological oral microflora may lead to an accumulation
of the highly carcinogenic intermediate acetaldehyde. This study was
conducted to evaluate the role of dental status on the microbial
production of acetaldehyde from ethanol in saliva. The microbial
acetaldehyde production from ethanol was related to the dental score in
132 volunteers. After adjustment for smoking, alcohol consumption, age
and gender, poor dental status was shown to lead to an approximately
twofold increase in salivary acetaldehyde production from ethanol
(P=0.02). Our results could be an important factor underlying the role
of poor dental hygiene and status in oral cancer risk associated with
ethanol drinking.
12
UI - 11167144
AU - Ravi D; Ramadas K; Mathew BS; Panikkar KR; Nair MK; Pillai MR
TI -
Apoptosis, angiogenesis and proliferation: trifunctional measure of
tumour response to radiotherapy for oral cancer.
SO - Oral Oncol 2001 Feb;37(2):164-71
AD - Division of Laboratory Medicine, Regional Cancer Centre,
Thiruvananthapuram, Kerala State 695011, India.
Local recurrence is a significant problem following radiotherapy in oral
carcinoma and hence there is a paramount need for predictive markers.
This study therefore analysed the predictive value of pre-treatment
status of angiogenesis, apoptosis, expression of apoptosis regulatory
p53, bax and bcl-2 proteins as well as tissue proliferation in relation
to tumour response to radiotherapy. Sixty-nine histologically defined
invasive carcinoma lesions were included in the study. Extent of
apoptosis was defined morphologically and by the TUNEL (Tdt-mediated
dUTP biotin nick end labelling) assay. Expression of apoptosis
regulatory p53, bax and bcl-2 proteins were evaluated by
immunocytochemistry. Mutant p53 protein was detected using a mutant
p53-specific ELISA. The extent of tissue proliferation was evaluated by
cyclin D1 expression. Angiogenesis was evaluated by CD34 antigen
expression. All patients were treated with radical radiotherapy and
followed up for 36 months. High levels of p53 protein detected by
immunocytochemistry were found to be associated with poor response to
treatment or disease relapse. Detection of mutant p53 protein also
showed significant association with poor prognosis. Low levels of
angiogenesis had a correlation with recurrence status. Tumours showing
less vascularisation as well as increased apoptosis had a poor
prognosis. Expression of p53 and bcl-2 proteins showed direct
correlation with angiogenesis. There was no correlation between clinical
status and any of the experimental parameters with histopathological
grades of invasive lesions. Presence of mutant p53 protein is suggestive
of poor tumour response to radiotherapy. Expression of p53 and increased
apoptosis in less vascularised tumours is associated with treatment
resistance. A predictive assay based on these results designed to
analyse individual tumour samples showed presence of apoptotic cells
near the vasculature to be indicative of good prognosis, while absence
of apoptotic cells or highly proliferative cells and/or expression of
bcl-2 protein in cells around the vasculature to be an indicator of poor
prognosis.
13
UI - 11167146
AU - Ikuta M; Podyma KA; Maruyama K; Enomoto S; Yanagishita M
TI -
Expression of heparanase in oral cancer cell lines and oral cancer
tissues.
SO - Oral Oncol 2001 Feb;37(2):177-84
AD - Oral Surgery, Department of Oral Restitution, Division of Oral Health
Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima,
Bunkyo-ku, Tokyo 113-8549, Japan. ikuta.osur@tmd.ac.jp
In the process of metastasis, cancer cells secrete several enzymes which
degrade extracellular matrices (ECMs) and basement membranes (BMs) of
blood vessels. One of them, heparanase, has been reported to be an
important enzyme when metastatic cancer cells invade blood vessels. The
enzyme cleaves heparan sulfate (HS), a main component of ECM and BM. In
the present study, HS-degrading ability of several human oral cancer
cell lines (HSC2, HSC3, HSC4, Ca9-22, NA, ACC3 and Ab-J) and tissues
derived from human oral squamous cell carcinomas (both metastatic and
non-metastatic) were investigated by measuring heparanase activities and
levels of heparanase mRNA by a quantitative reverse
transcriptase-polymerase chain reaction. The catalytic activities and
the mRNA levels of heparanase showed a good agreement. Clinical
demonstration of cancer metastasis generally correlated with high levels
of heparanase activity and its mRNA. The results suggest that heparanase
activity and its mRNA level are good diagnostic parameters for
evaluating the metastatic properties of human oral cancer cells.
14
UI - 11167149
AU - Poulopoulos AK; Antoniades K; Kiziridou A
TI -
Bilateral metastatic breast angiosarcoma to the mandibular gingiva: case
report.
SO - Oral Oncol 2001 Feb;37(2):199-201
AD - Department of Oral Medicine and Pathology, Dental School, Aristotle
University of Thessaloniki, Thessaloniki, Greece.
Metastases to the jaws and oral soft tissues are rare. A case of breast
angiosarcoma metastatic to the mandible and the gingiva, bilaterally in
the premolar area is presented. The clinical, histological features and
the management of the metastatic oral lesions are reported. Our case
emphasises the possibility that in patients with history of breast
angiosarcoma, oral inflammatory-like lesions may be an indication of a
metastatic deposit.
15
UI - 11036243
AU - Al-Rajhi N; Khafaga Y; El-Husseiny J; Saleem M; Mourad W; Al-Otieschan
TI -
A; Al-Amro A
Early stage carcinoma of oral tongue: prognostic factors for local
control and survival.
SO - Oral Oncol 2000 Nov;36(6):508-14
AD - Department of Radiation Oncology, MBC 34, King Faisal Specialist
Hospital and Research Center, PO Box 3354, 11211, Riyadh, Saudi Arabia.
nrajhi@kfshrc.edu.sa
The purpose of this study was to assess prognostic factors, treatment
outcomes and patterns of relapse in patients with early stage (T1-2 N0)
squamous cell carcinoma of oral tongue treated primarily by surgery. The
medical records of all patients with early stage (T1-2 N0) oral tongue
cancer, radically treated at King Faisal Specialist Hospital and
Eighty-five patients were identified for analysis, 38 male and 47
female. With a median follow-up for surviving patients of 64 months,
5-year actuarial overall, disease-specific (DSS), and relapse-free
survival (RFS) were 71, 75, and 63%, respectively. Univariate analysis
for DSS showed survival advantage for patients with tumor thickness (TT)
of < or =10 mm (P=0.0002) and distance from resection margin (DFRM) of >
5 mm (P=0.005). The effect of TT of < or =10 mm was maintained (P=0.001)
on multivariate analysis. Higher RFS was observed with TT of < or =10 mm
(P=0.0002), DFRM of > 5 mm (P=0.0002) and DFRM of >10 mm (P=0.007). On
multivariate analysis higher RFS was also found for TT < or =10 mm
(P=0.01) and DFRM >5 mm (P=0.01). Salvage of local tongue recurrence was
higher than neck node failure, with 5-year DSS of 71 and 19%,
respectively (P=0.007). Time interval for recurrence showed no
significant impact on outcome. In T1-2 N0 oral tongue cancer, TT, and
DFRM are significant prognostic factors for both local control and
survival. Neck node recurrence is associated with poor prognosis and low
salvage rate.
16
UI - 11036245
AU - Lo Muzio L; Favia G; Mignogna MD; Piattelli A; Maiorano E
TI -
Primary intraoral leiomyosarcoma of the tongue: an immunohistochemical
study and review of the literature.
SO - Oral Oncol 2000 Nov;36(6):519-24
AD - Department of Dentistry and Surgery, University of Bari, Bari, Italy.
llomuzio@tin.it
Leiomyosarcoma is a relatively uncommon mesenchymal tumor that exhibits
smooth-muscle differentiation. We report a new case of leiomyosarcoma
involving the tongue of a 67-year-old male. Histologically, the tumor
was composed of variably oriented fascicles of spindle-shaped cells with
'cigar-shaped' nuclei and eosinophilic cytoplasm, containing occasional
PAS-positive granules. Atypical mitotic figures and necrotic foci were
frequently detected. Consistent desmin, alpha-smooth muscle-specific and
sarcomeric actin, and vimentin immunoreactivity was demonstrated in the
tumor cells, whereas cytokeratins, CD 30, CD 31, CD 34, CD 45, CD 68,
EMA, GFAP, HMB 45 and S-100 protein were negative. The patient underwent
wide surgical excision of the tumor and is alive and disease-free at a
5-year follow-up. This report emphasizes the difficulties in the
differential diagnosis of these uncommon tumors in an intra-oral
location.
17
UI - 11036246
AU - Nunes DN; Kowalski LP; Simpson AJ
TI -
Detection of oral and oropharyngeal cancer by microsatellite analysis in
mouth washes and lesion brushings.
SO - Oral Oncol 2000 Nov;36(6):525-8
AD - Laboratory of Cancer Genetics, Ludwig Institute for Cancer Research, Rna
Prof. Antonio Prudente, 109 - 4th floor, 01509-010, SP, Sao Paulo,
Brazil.
Microsatellite allele losses are characteristic features of head and
neck squamous cell carcinoma and can be used as molecular markers for
malignancy. We have investigated the detection of microsatellite allele
loss in mouth washes and lesions brushings from 19 patients with
squamous cell carcinoma of the oral cavity and oropharynx as a means of
tumour detection. In 84% of the analysed cases, allele loss previously
identified in the tumour of these patients, was detected in these easily
obtained specimens. No alterations were found in material derived from
10 healthy individuals. Success of detection was independent of tumour
stage, suggesting that this approach may be useful for early diagnosis
as well as for follow-up.
18
UI - 11036247
AU - Rogers SN; Lowe D; Humphris G
TI -
Distinct patient groups in oral cancer: a prospective study of perceived
health status following primary surgery.
SO - Oral Oncol 2000 Nov;36(6):529-38
AD - Regional Maxillofacial Unit, University Hospital Aintree, Fazakerley, L9
1AL, Liverpool, UK.
Health-related quality of life (HRQOL) is an important consideration in
the management of patients with cancer. Pre-treatment data can give an
indication of the anticipated response following cancer treatment.
However, in order to use HRQOL data meaningfully it is essential to have
an appreciation of how different patient groups respond. The aim of the
study was to identify distinct patient groups at baseline using the
University of Washington head and neck cancer questionnaire (UW-QOL). It
was also the intention to see how these groups differed in their: (1)
clinical and demographic attributes; (2) European Organisation for
Research and Treatment of Cancer (EORTC) C30 and SF 36 scores; and (3)
longitudinal trends over 6 and 12 months. One-hundred and thirty
consecutive patients with previously untreated oral and oro-pharyngeal
cancer were recruited. All were treated by primary surgery. Attrition
was evident in the study but care was taken to allow for this. There
were two distinct groups of patients identified by the cumulative UW-QOL
score at presentation. These groups discriminated throughout the EORTC
C30 and SF 36, at baseline and longitudinally, with the exception of
mental health. This study demonstrates that HRQOL items are
interrelated. There are difficulties in using baseline scores for
treatment selection, and scores need to be interpreted in the light of
clinical and demographic factors.
19
UI - 11036248
AU - Yao L; Zhao YL; Itoh S; Wada S; Yue L; Furuta I
TI -
Thrombospondin-1 expression in oral squamous cell carcinomas:
correlations with tumor vascularity, clinicopathological features and
survival.
SO - Oral Oncol 2000 Nov;36(6):539-44
AD - Department of Oral and Maxillofacial Surgery, Faculty of Medicine,
Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama,
Japan. y6043604@ms.toyama-mpu.ac.jp
Thrombospondin-1 (TSP-1) is a 450 kd glycoprotein synthesized and
incorporated into the extracellular matrix by numerous cell types and
reported to suppress tumor growth and progression by its inhibition of
angiogenesis. In order to clarify the biological role of TSP-1 and
determine its clinicopathological significance in oral squamous cell
carcinomas (SCCs), we identified TSP-1 protein expression in 54 oral
SCCs by immunohistochemistry and correlated it with microvessel density
(MVD), clinicopathological features and patient's survival. Thirty-two
out of 54 carcinomas (59%) were identified as having a low level of
TSP-1 expression (TSP-1-L), and 22/54 (41%) carcinomas identified as
having a high level of TSP-1 expression (TSP-1-H). The MVD counts
(mean+/-S.D.=9.0+/-4.9) in TSP-1-H tumors was significantly lower than
that (mean+/-S.D.=12.7+/-4.4) in TSP-1-H tumors (P=0.0065). The level of
TSP-1 expression was not correlated with T category and histologic
grade, but inversely correlated with the pattern of tumor invasion
(P=0.0136) and with lymph nodal status (P=0.0119). Furthermore,
Kaplan-Meier analysis showed that the 5-year survival rate of TSP-1-H
group was significantly higher than that of TSP-l-L group. Our results
suggested that TSP-1 expression exerts an inhibitory effect on tumor
vascularity, and that it has value in assessment of aggressiveness and
prognosis of oral SCCs.
20
UI - 11036249
AU - Sato S; Miyauchi M; Takekoshi T; Zhao M; Kudo Y; Ogawa I; Kitagawa S;
TI -
Fujita M; Takata T
Reduced expression of CD44 variant 9 is related to lymph node metastasis
and poor survival in squamous cell carcinoma of tongue.
SO - Oral Oncol 2000 Nov;36(6):545-9
AD - Department of Oral Pathology, Faculty of Dentistry, Hiroshima
University, 1-2-3 Kasumi, Minami-ku, 734-8553, Hiroshima, Japan.
Expression of CD44v9 was immunohistochemically studied in 120 biopsy
specimens from primary squamous cell carcinoma (SCC) of the tongue and
correlated with clinicopathological findings of the SCCs. The tumors
were classified into three groups according to immunostaining pattern of
CD44v9; 53 cases with distinct positivity in all cancer cells except for
those in the central part of nests (Group 1, non-reduced group), 42
cases with reduced expression in peripheral cells of nests (Group 2,
reduced group), and 25 cases with complete disappearance of the
expression in one or more nests (Group 3, negative group). Nineteen of
25 (76%) tumors in Group 3 and 14 of 42 (33%) in Group 2 exhibited lymph
node metastasis, compared with only 8 of 53 (15%) in Group 1. The
average survival time in Groups 1, 2 and 3 was 4496+/-204, 3866+/-379
and 2719+/-359 days, respectively and became shorter with the reduction
of CD44v9 expression. These results suggest that the down-regulation of
CD44v9 in SCC of the tongue may relate to the detachment of tumor cells
from primary lesions, establishment of lymph node metastasis and
consequently the death of patients.
21
UI - 11036251
AU - Richards A; Costelloe MA; Eveson JW; Scully C; Irvine GH; Rooney N
TI -
Oral mucosal non-Hodgkin's lymphoma--a dangerous mimic.
SO - Oral Oncol 2000 Nov;36(6):556-8
AD - University of Bristol Dental Hospital, Lower Maudlin Street, BS1 2LY,
Bristol, UK.
Reports of T-cell lymphomas in the oral cavity are rare. Most have
presented as a persisting ulcerated swelling. This paper reports two
men, one of whom presented with a short history of increasing facial
swelling and pain apparently related to a lower premolar tooth, and the
other who had recurrent oral ulceration in several sites over a period
of years. These types of cases are likely to present initially to
general dental practitioners.
22
UI - 11120478
AU - Prime SS; Thakker NS; Pring M; Guest PG; Paterson IC
TI -
A review of inherited cancer syndromes and their relevance to oral
squamous cell carcinoma.
SO - Oral Oncol 2001 Jan;37(1):1-16
AD - Department of Oral and Dental Science, University of Bristol, Lower
Maudlin Street, BS1 2LY, Bristol, UK. stephen.prime@bristol.ac.uk
This paper examines the genetic defects associated with inherited cancer
syndromes and their relevance to oral cancer. Tumour suppressor genes
are now thought of as either gatekeepers or caretakers according to
whether they control cell growth directly by inhibiting cell
proliferation and/or promoting cell death (gatekeepers) or whether they
maintain the integrity of the genome by DNA repair mechanisms
(caretakers). In disorders such as xeroderma pigmentosum, ataxia
telangiectasia, Bloom syndrome and Fanconi's anaemia, where there are
defective caretaker genes, there is an increased incidence of second
primary malignancies, including oral cancer. By contrast, with the
exception of Li Fraumeni syndrome, abnormalities of gatekeeper genes do
not predispose to oral cancer. Not only do Li Fraumeni patients develop
second primary malignancies, but defects of the p53 pathway (p53
mutation, MDM2 over-expression, CDKN2A deletion) appear to be a
ubiquitous feature of sporadic oral cancer as it occurs in the West. The
findings suggest that genetic instability is of fundamental importance
in the pathogenesis of oral cancer.
23
UI - 11120491
AU - Pandey M; Thomas G; Somanathan T; Sankaranarayanan R; Abraham EK; Jacob
TI -
BJ; Mathew B; The Trivandrum Oral Cancer Screening Study Group
Evaluation of surgical excision of non-homogeneous oral leukoplakia in a
screening intervention trial, Kerala, India.
SO - Oral Oncol 2001 Jan;37(1):103-9
AD - Regional Cancer Centre, Medical College Campus, Trivandrum, 695011,
Kerala, India. manojpandey@vsnl.com
It is well established that most invasive oral cancers arise from
precancerous lesions such as leukoplakia, erythroplakia and oral
submucous fibrosis. One of the approaches for control of oral cancer is
to detect oral precancerous lesions early in their development and
prevent their malignant transformation to invasive cancer either by
chemoprevention or by surgical excision of the lesions, with concurrent
control of tobacco and alcohol use and other specific aetiological
factors. However, the value of specific approaches such surgery in
long-term control of lesions and prevention of malignant transformation
is not known. We describe our experience with cold knife surgical
excision of 59 cases of non-homogeneous leukoplakia of the oral cavity
diagnosed in the context of a community-based oral cancer cluster
randomised oral cancer screening trial in Kerala, India. Two-thirds of
these revealed dysplasia on histology. After a minimum follow-up of 12
months (range 12-37 months) after surgical excision, 44 (74.8%) were
remaining disease free with no evidence of recurrent/new lesions; during
follow-up, three (5%) developed new luekoplakic lesions, and six (10.1%)
developed recurrent lesions, while six (10.1%) could not be traced after
treatment. There was no event of malignant change during follow-up. The
proportion of subjects remaining with no evidence of disease at 3 years
by Kaplan-Meier method of analysis was 62.1% (95% CI: 0.36-0.87).
Accrual and long-term follow-up of large number of surgically treated
cases may provide valuable leads to management policies of oral
leukoplakia, since, as of now, the added value of specific treatments
over and above primary prevention by tobacco and alcohol control remains
to be established.
<
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
